Alkem Laboratories Q2 profit falls 12%! watch

The sequential performance was stronger: - Revenue increased 21.7% quarter-on-quarter. - Net profit increased 29.88% quarter-on-quarter. This indicates an improvement compared with Q1 FY27, even though year-on-year net profit remained lower. Segment-wise performance The company's regional business performance showed different growth rates: 1. India sales: Increased 9.5% to ₹3,027.5 crore. 2. International sales: Increased 22.3% to ₹1,454 crore. 3. US sales: Increased 2.4% to ₹783 crore. 4. Non-US sales: Increased 58% to ₹671 crore. 5. Biotech sales: Declined 35% to ₹70.4 crore. The chronic segment in India grew 22.4%, outperforming the reported Indian pharmaceutical market growth of 16%.